Isolation of a nuclease-resistant decoy RNA that can protect human acetylcholine receptors from myasthenic antibodies

Nature Biotechnology

Volumn 15, Issue 1, 1997, Pages 41-45

  Lee, Seong Wook ^a   Sullenger, Bruce A ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Acetylcholine receptor; Autoantibody; Decoy RNA; In vitro selection; Myasthenia gravis

Indexed keywords

AUTOANTIBODY; CHOLINERGIC RECEPTOR; CHOLINERGIC RECEPTOR ANTIBODY; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY 198; RNA; UNCLASSIFIED DRUG;

ANTIGEN BINDING; ARTICLE; CONTROLLED STUDY; HUMAN; HUMAN CELL; MUSCLE FATIGUE; MUSCLE WEAKNESS; MYASTHENIA GRAVIS; PRIORITY JOURNAL; RECEPTOR DOWN REGULATION; RNA BINDING;

ANIMALS; ANTIBODIES, MONOCLONAL; AUTOANTIBODIES; BASE SEQUENCE; BINDING SITES; CLONING, MOLECULAR; DOWN-REGULATION; EPITOPES; HUMANS; MOLECULAR SEQUENCE DATA; MYASTHENIA GRAVIS; RATS; RECEPTORS, CHOLINERGIC; RHABDOMYOSARCOMA; RIBONUCLEASES; RNA; SUBSTRATE SPECIFICITY; TUMOR CELLS, CULTURED;

EID: 0031031521     PISSN: 10870156     EISSN: 15461696     Source Type: Journal    
DOI: 10.1038/nbt0197-41     Document Type: Article

References (34)

1. Lindstrom, J., Shelton, D., and Fujii, Y. 1988. Myasthenia gravis. Adv. Immunol. 42:233-284.
2. Wilcox, N. 1993. Myasthenia gravis. Curr. Opin. Immunol. 5:910-917.
3. Drachman, D.B. 1994. Myasthenia gravis. W. Engl. J. Med. 330:1797-1810.
4. Patrick, J. and Lindstrom, J.M. 1973. Autoimmune response to acetylcholine receptor. Science 180:871-872.
5. Fambrough, D.M., Drachman, D.B., and Satiamurti, S. 1973. Neuromuscular junction in myasthenia gravis: decreased acetylcholine receptors. Science 182:293-295.
6. Tzartos, S.J., Rand, D.E., Einarson, B.L., and Lindstrom, J.M. 1981. Mapping o1 surface structures of electrophorous acetylcholine receptor using monoclonal antibodies. J. Biol. Chem. 256:8635-8645.
7. Tzartos, S.J., Seybold, M.E., and Lindstrom, J.M. 1982. Specificities of antibodies to acetylcholine receptors in sera from myasthenia gravis patients measured by monoclonal antibodies. Proc. Watt Acad. Sci. USA 79:188-192.
8. Sullenger, B.A., Gallardo, H.F., Ungere, G.E., and Gilboa, E.1990. Overexpression of TAR sequences renders cells resistant to human immunodeficiency virus replication. Cell 63:601-608.
9. Sullenger, B.A., Gallardo, H.F., Lingers, G.E., and Gilboa, E. 1991. Analysis of TAR decoy RNA mediated inhibition of HIV-1 transactivation. J. Virol. 65:6811-6816.
10. Lisziewicz, J., Rappaport, J., and Dhar, R. 1991. Tat-regulated production of multimerized TAR RNA inhibits HIV-1 gene expression. New Biol. 3:82-89.
11. Lee, S.-W., Gallardo, H.F., Gilboa, E., and Smith, C. 1994. Inhibition of HIV-1 in human T-cells by a potent RRE decoy comprised of the 13 nucleotide-long minimal rev binding domain. J. Virol. 68:8254-8264.
12. Lee, S.-W., Gallardo, H.F., Gasper, O., Smith, C, and Gilboa, E. 1995. Inhibition of HIV-1 in CEM cells by a potent TAR decoy. Gene Ther. 2:377-384.
13. Gold, L, Allen, P., Binkley, J., Brown, D., Schneider, D., Eddy, S.R., et al. 1993. RNA: the shape of things to come, pp. 497-510 in The RNA world. Gestelend, R.F and Atkins, J. F. (eds.). Cold Spring Harbor Press, Cold Spring Harbor, NY.
14. Gold, L, Polisky, B., Uhlenbeck, O.C., and Yarus, M. 1995. Diversity of oligonucleotide functions. Annu. Rev. Biochem. 64:763-795.
15. Tuerk, C. and Gold, L. 1990. Systematic evolution of ligands by exponential enrichment: RNA ligands to bacteriophage T4 DNA polymerase. Science 249:505-510.
16. Joyce, G.F. 1989. Amplification, mutation and deletion of catalytic RNA. Gene 82:83-87.
17. Szostak, J.W. 1992. In vitro genetics. Trends Biochem. Sci. 17:89-93.
18. Tsai, D.E., Kenan, D.J., and Keene, J.D. 1992. In vitro selection of an RNA epitope immunologically cross-reactive with a peptide. Proc. Watt Acad. Sci. USA 89:8864-8868.
19. Doudna, J.A., Cech, T.R., and Sullenger, B.A. 1995. Selection of an RNA molecule that mimics a major autoantigenic epitope of human insulin receptor. Proc. Watt Acad. Sci. USA 92:2355-2359.
20. Lee, S.-W. and Sullenger, B.A. 1996. Isolation of a nuclease-resistant decoy RNA that selectively blocks autoantibody binding to insulin receptors on human lymphocytes. J. Exp. Med. 184:315-324.
21. Saedi, M.S., Anand, R., Conroy, W.G., and Lindstrom, J.M. 1990. Determination of amino acids critical to the main immunogenic region of intact acetylcholine receptors by in vitro mutagenesis. FEBS Lett. 267:55-59.
22. Pieken, W.A., Olsen, D.B., Benseier, F., Aurup, H., and Eckstein, F 1991. Kinetic characterization of ribonuclease-resistant 2′-modified hammerhead rlbozymes. Science 253:314-317.
23. Jellinek, D., Green, LS., Bell, C, Lynott, C.K., Gill, N., Vargeese, C, et al. 1995. Potent 2′amino-2′deoxy RNA inhibitors of basic fibroblast growth factor. Biochemistry 34:11363-11372.
24. Sophianos, D. and Tzartos, S. 1989. Fab fragments of monoclonal antibodies protect the human acetylcholine receptor against antigenic modulation caused by myasthenia gravis. J. Autoimmun. 2:777-789.
25. Mamalaki, A., Trakas, N., and Tzartos, S.J. 1993. Bacterial expression of a single-chain Fv fragment which efficiently protects the acetylcholine receptor against antigenic modulation caused by myasthenic antibodies. Eur. J. Immunol. 23:1839-1845.
26. Stanley, E.F. and Drachman, D.B. 1978. Effect of myasthenic immunoglobulin of acetylcholine receptors of intact mammalian neuromuscular junctions. Science 200:1285-1287.
27. Kao, I. and Drachman, D.B. 1977. Myasthenic immunoglobulin accelerates acetylcholine receptor degradation. Science 196:527-529.
28. Heineman, S., Beven, S., Kullberg, R., Lindstrom, J.M., and Rice, J. 1977. Modulation of acetylcholine receptor by antibody against the receptor. Proc. Natl. Acad. Sci. USA 74:3090-3094.
29. Drachman, D.B., Adams, R.N., Josifek, L.F., and Self, S.G. 1982. Functional activities of autoantibodies to acetylcholine receptors and the clinical severity of myasthenia gravis. W. Engl. J. Med. 307:769-775.
30. Jaeger, J., Turner, D., and Zuker, M. 1989. Improved predictions of secondary structures for RNA. Proc. Watt Acad. Sci. USA 86:7706-7710.
31. Vincent, A., Whiting, R.J., Schluep, M., Heidenreich, F., Lang, B., Roberts, A., et al. 1987. Antibody heterogeneity and specificity in myasthenia gravis. Ann. N.Y. Acad. Sci. 505:106-120.
32. Lennon, V.A., Lambert, E.H., Leiby, K.R., Okarma, T.B., and Talib, S. 1991. Recombinant human acetylcholine receptor ct-subunit induces chronic experimental autoimmune myasthenia gravis. J. Immunol. 146:2245-2248.
33. Stratton, M.R., Darling, J., Pikington, G.J., Lantos, PL., Reeves, B.R., and Cooper, CS. 1989. Characterization of the human cell line TE671. Carcinogenesis 10:899-905.
34. Luther, M.A., Schoepfer, R., Whiting, P., Casey, B., Blatt, Y, Mortal, M.S., Montai, M., et al. 1989. A muscle acetylcholine receptor is expressed in the human cerebellar medulloblastoma cell line TE671. J. Neurosci. 9:1082-1096.